Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “rLP2086”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)Study completedNCT01299480
What this trial is testing

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Who this might be right for
Meningococcal Vaccine
Pfizer 1,714
Early research (Phase 1)Study completedNCT00879814
What this trial is testing

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Who this might be right for
Meningitis, Meningococcal
Pfizer 48
Testing effectiveness (Phase 2)Ended earlyNCT00798304
What this trial is testing

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Who this might be right for
Meningitis, Meningococcal
Pfizer 46
Testing effectiveness (Phase 2)Study completedNCT00780806
What this trial is testing

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

Who this might be right for
Meningitis, Meningococcal
Wyeth is now a wholly owned subsidiary of Pfizer 60
Large-scale testing (Phase 3)Study completedNCT01543087
What this trial is testing

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Who this might be right for
Meningococcal Infection
Pfizer 698
Testing effectiveness (Phase 2)Study completedNCT01461980
What this trial is testing

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Who this might be right for
VaccinesMeningococcal Vaccines
Pfizer 2,648
Testing effectiveness (Phase 2)Study completedNCT01323270
What this trial is testing

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Who this might be right for
Meningococcal VaccinerLP2086Repevax+2 more
Pfizer 753
Early research (Phase 1)Study completedNCT00387569
What this trial is testing

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

Who this might be right for
Healthy
Wyeth is now a wholly owned subsidiary of Pfizer 99
Testing effectiveness (Phase 2)Study completedNCT00387725
What this trial is testing

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

Who this might be right for
Healthy
Pfizer 127
Testing effectiveness (Phase 2)Study completedNCT02534935
What this trial is testing

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Who this might be right for
Meningococcal B Disease
Pfizer 396
Large-scale testing (Phase 3)Study completedNCT03135834
What this trial is testing

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Who this might be right for
Meningococcal Vaccine
Pfizer 1,610
Early research (Phase 1)Study completedNCT00297687
What this trial is testing

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Who this might be right for
Meningitis, Meningococcal
Wyeth is now a wholly owned subsidiary of Pfizer 108
Testing effectiveness (Phase 2)Study completedNCT00808028
What this trial is testing

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Who this might be right for
Meningitis, Meningococcal
Pfizer 538
Large-scale testing (Phase 3)Study completedNCT01352845
What this trial is testing

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Who this might be right for
Healthy
Pfizer 3,301
Testing effectiveness (Phase 2)Study completedNCT01461993
What this trial is testing

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Who this might be right for
VaccinesMeningococcal Vaccines
Pfizer 2,499
Large-scale testing (Phase 3)Study completedNCT01830855
What this trial is testing

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Who this might be right for
Meningococcal Vaccine
Pfizer 3,596
Testing effectiveness (Phase 2)Study completedNCT01768117
What this trial is testing

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Who this might be right for
Meningitis, Meningococcal, Serogroup B
Pfizer 13
Testing effectiveness (Phase 2)Study completedNCT02531698
What this trial is testing

Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Who this might be right for
MENINGOCOCCAL INFECTION
Pfizer 400
Large-scale testing (Phase 3)Study completedNCT01352793
What this trial is testing

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Who this might be right for
Meningitis, Meningococcal
Pfizer 5,715